Clinical Trials Logo

Filter by:
NCT ID: NCT04433078 Withdrawn - SARS-CoV-2 Clinical Trials

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

STORM
Start date: June 22, 2020
Phase: Phase 2
Study type: Interventional

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected patients. A secondary aim is to identify genetic variants that predict either an unusually mild disease or an unusually severe disease - knowledge that can be used to design new and precise medications and to be able to predict patients who might get into early trouble and to therefore hospitalize them.

NCT ID: NCT04432766 Withdrawn - COVID-19 Clinical Trials

A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients

Start date: October 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized study to assess safety, pharmacokinetics, immunogenicity, and efficacy of BAT2020 in hospitalized patients infected with COVID-19. This study is composed of 2 Parts: a single ascending dose (Part 1) and single dose(s) tested in parallel with a double-blind, placebo-controlled design (Part 2). Patients also will receive best available standard of care (SOC) treatment. A data and safety monitoring board (DSMB) will be set up for the study.

NCT ID: NCT04432350 Withdrawn - COVID Clinical Trials

Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications

Start date: June 12, 2020
Phase:
Study type: Observational

This retrospective cohort study will include eligible patients that received a positive COVID-19 test and filled a new prescription for one of the repurposed medications (including hydroxychloroquine, chloroquine, with or without azithromycin) for the treatment of COVID-19 at a PrescribeWellness pharmacy. The study will use de-identified data collected from February 1, 2020 to start of study. The data set will include: repurposed medication name, strength, and dose; age (age limit set at 89 years old); gender; provider type; zip code (excludes 17 three-digit zip code tabulation areas that have a population of 20,000 or fewer persons); conditions; mortality; and a list of concomitant prescriptions.

NCT ID: NCT04431193 Withdrawn - Clinical trials for Osteoarthritis, Knee

Estimate Serum Oxytocin PD Range in the Periphery

Start date: December 2023
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to define the maximum effect oxytocin (naturally occurring hormone that is made in the brain) has on pain from a 5 minute heat probe applied to the skin and to get an estimate for the relationship between the amount of pain relief at different amounts of oxytocin in the blood. This is a study of participants that will receive an intravenous (IV) infusion of oxytocin (naturally occurring hormone that is made in the brain) with blood samples taken thereafter in order to create a formula to describe the concentrations of oxytocin in the blood over time (pharmacokinetics). In this study healthy volunteers and people with knee arthritis so severe that there is a need for a joint replacement are recruited for a one day study. Each study participant will have 2 IV catheters placed (one in each arm). After placement of the IV catheters, 4 different levels of oxytocin will be given by IV infusion. Blood samples will be taken before the infusion begins and after each different level of the infusion. The blood will be drawn through the second IV catheter. The study team will also do some tests to get a rough idea of how oxytocin changes perceptions on the skin and how this relates to the amount of oxytocin in the blood at the same time. The study team will study a painful perception by placing a probe on the skin and heating it to 113 degrees Fahrenheit for 5 minutes. Each study participant will score any pain that is experienced on a 0 to 10 scale.

NCT ID: NCT04430959 Withdrawn - Clinical trials for Bipolar Disorder Depression

Candesartan as an Adjunctive Treatment for Bipolar Depression

Start date: October 1, 2020
Phase: Early Phase 1
Study type: Interventional

This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.

NCT ID: NCT04429204 Withdrawn - Mesothelioma Clinical Trials

Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

This trial evaluates if cryoablation will stimulate a local immune response by cluster of differentiation 8 positive (CD8+) cells which are not present in ablation naive regions of the tumors in patients with mesothelioma. Cryoablation uses extreme cold to damage or destroy tumor lesions. Mesothelioma is a rare cancer that grows and spreads quickly, and has low survival rates. The information learned from this study may provide evidence as to whether there is a measurable, local immune response from cryoablation. Studying samples of mesothelioma tissue in the laboratory from patients who have undergone biopsy may help doctors learn more about the effects of cryoablation on cells. It may also help doctors understand how well patients respond to treatment.

NCT ID: NCT04428931 Withdrawn - Parkinson's Disease Clinical Trials

Attentional Performance in Parkinson Disease

Start date: December 6, 2021
Phase:
Study type: Observational

Background: Parkinson Disease (PD) is a nervous system disorder that affects movement. Dopamine is an important neurotransmitter in the brain. As PD progresses, there is less and less dopamine in the brain. Researchers think there may be a relationship between differences in attention and dopamine in people with PD. Objective: To learn if people with PD that is worse on one side also have differences in how much attention they pay to the two sides of space on their left and right. Eligibility: English-speaking, right-handed people age 35-80 with PD. Design: Participants will be screened with medical and neurological history and exam, and medicine review. Participants will have 1 study visit. It will last 7-8 hours. They will stop taking their Parkinson medicine 12 hours before the visit. Participants will complete questionnaires. Participants will do tasks on a computer screen. They will judge the middle of lines, react to stimuli, and search and identify items that appear on the screen. Participants may have functional and structural magnetic resonance imaging (MRI). MRI uses a strong magnetic field and radio waves to take pictures of the brain. During the MRI, participants will lie on a table that slides in and out of the MRI scanner. While inside the scanner, they will look at a cross on a screen, relax, and think about nothing. Participants will undergo prism adaptation. They will sit in front of a board while their chin rests on a support. They will point to 1 of 2 dots on the board while they wear prism glasses that shift their vision to the left or right....

NCT ID: NCT04428918 Withdrawn - Clinical trials for Hematologic Malignancies

Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation

Start date: June 5, 2020
Phase:
Study type: Observational

Background: Allogenic hematopoietic cell transplantation (HCT) is a procedure in which a person gets stem cells from a donor in order to treat their disease. Researchers want to collect samples from people who have had or will have HCT. They will perform tests on the samples to study the immune system and its response to infections and disease. Objective: To collect biological samples from people who have had or are planning to have HCT to treat primary immunodeficiencies, blood cancers, or disorders of T-cell proliferation and/or dysregulation. Eligibility: People age 8 years and older who have undergone or are planning to undergo HCT. Design: Participants will be screened with: Medical history Medical chart review Physical exam Blood tests. Participants may give blood and urine samples. Participants may have a skin biopsy. Participants may undergo apheresis. For this, a needle will be placed into an arm vein to take blood. A machine divides the whole blood into parts. The sample cells are taken out and the rest of the blood is returned through a second needle in the other arm. Participants may have a bone marrow aspiration and biopsy. For this, the hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle. Participants may have a tumor or other abnormal tissue biopsy. For this, a tissue sample is obtained using a needle and syringe. They will sign a separate consent form. They may have a body scan or ultrasound to help locate the tumor during the biopsy. Participation lasts for as long as participants choose to give samples.

NCT ID: NCT04428242 Withdrawn - Clinical trials for Macular Degeneration

Study Evaluating Retinal Health Monitoring System Thickness Module

Start date: April 2020
Phase:
Study type: Observational

Evaluate the ability and accuracy of the Retinal Health Monitoring System - Retinal Thickness Module (RHMS - RTM).

NCT ID: NCT04427228 Withdrawn - Brain Metastases Clinical Trials

Single vs Multi-fraction SRS Patients on Immunotherapy

MIGRAINE
Start date: June 29, 2020
Phase: Phase 2
Study type: Interventional

This study is meant to compare different surgical approaches to brain cancer.